Categories: Automobile

Kia Announces July 2025 Global Sales Results

  • July 2025 global sales of 262,705 units, up 0.3% Y/y
  • Outside of Korea, Kia sold 217,188 units, up 0.9% Y/y
  • Kia RVs led the company’s sales, including Sportage, Seltos and Sorento
  • Solid sales performance was fueled by steady growth in EV and hybrid models

Kia Corporation today announced total global sales of 262,705 units in July 2025, a 0.3 percent increase year over year.

- Advertisement -

Robust sales were driven by constant growth in EV and hybrid models, while strong demand continued for core RV lineup like the Sportage and Seltos SUV.

- Advertisement -

Kia RVs led the company’s sales in July, with the Sportage SUV selling 46,901 units globally. The Seltos SUV backed up this strong market performance with sales of 28,538 units, followed by the Sorento SUV, which sold 17,852 units.

- Advertisement -

Sales outside of Korea

- Advertisement -

Sales outside of Korea, excluding special purpose vehicles, were up 0.9 percent compared with the same period in 2024, to 217,188 units.

- Advertisement -

In markets outside of Korea, the Sportage SUV led the brand’s momentum, recording 41,477 sales, followed by the Seltos SUV with 23,617 units. Combined sales of the K4 and K3, also known as Forte in some markets, totaled 16,813 units.

- Advertisement -

Korea sales

- Advertisement -

In July, Kia sold 45,017 units in the Korean market, a 2.2 percent decrease compared with the same period last year.

- Advertisement -

The Carnival MPV led the company’s passenger vehicle sales in its home market, with 7,211 units sold in July. The Sorento SUV followed, with sales of 7,053, while the Sportage SUV recorded sales of 5,424 units.

- Advertisement -

Kia aims to sustain its sales momentum with the EV lineup, including EV4, EV5 and PV5. By leveraging customer-centric strategies and strategic investments, the company continues to accelerate growth and strengthen its global electrification leadership.

- Advertisement -

Kia global sales – July 2025

- Advertisement -

July 2025

July 2024

YoY change

June 2025

MoM change

2025 YTD
(
July)

2024 YTD
(
July)

YTD change

Korea sales

45,017

46,010

-2.2%

46,003

-2.1%

321,440

321,250

0.1%

Overseas sales

217,188

215,188

0.9%

223,377

-2.8%

1,526,204

1,493,590

2.2%

Special Purpose Vehicle sales

500

600

-16.7%

647

-22.7%

2,597

2,655

-2.2%

Total sales

262,705

261,798

0.3%

270,027

-2.7%

1,850,241

1,817,495

1.8%

Editor’s note

- Advertisement -

* Sales results are based on wholesale unless otherwise specified
* Monthly sales figures provided in this release are unaudited and on a preliminary basis that may be subject to future update
* With the change in business results categorization in 2023, special purpose vehicle sales are recorded separately
* Special purpose vehicles include various specialized vehicles. Their sales figures account for sales in Korea and overseas markets

- Advertisement -
TheNews Market

Recent Posts

Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology

CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ -- Pierre Fabre Laboratories and Iktos, a global leader…

6 hours ago

3 E Network Technology Group Limited Announces Subsequent Closing of A US$2 Million Convertible Promissory Note Offering

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq:…

7 hours ago

Varonis Announces Date of Fourth Quarter and Full-Year 2025 Financial Results

January 09, 2026 16:05 ET  | Source: Varonis Systems, Inc. MIAMI, Jan. 09, 2026 (GLOBE…

7 hours ago

UK Solicitor Warns Against DIY Will Templates as January Searches Surge

New York City, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) --  A UK solicitor has warned…

7 hours ago

Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative Platform

LEAWOOD, Kan., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc., a biotechnology company focused…

7 hours ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

- Rapidly transforming into a leading global biopharma company January 09, 2026 18:01 ET  |…

7 hours ago